574705-92-3

Basic information

• Product Name: Pitavastatin Sodium
• Synonyms: Pitavastatin Sodium;(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt
• CAS NO: 574705-92-3
• Molecular Formula: C₂₅H₂₃FNO₄*Na
• Molecular Weight: 443.4425932
• Mol File: 574705-92-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pitavastatin Sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Pitavastatin Sodium(574705-92-3)
• EPA Substance Registry System: Pitavastatin Sodium(574705-92-3)

Safety Data

• Hazardous Substances Data: 574705-92-3(Hazardous Substances Data)

Usage

General Description

Pitavastatin Sodium is a chemical compound used mainly as an active ingredient in medications designed to lower cholesterol levels. It belongs to the class of drugs known as statins, which work by reducing the production of cholesterol in the liver. Pitavastatin Sodium improves overall cholesterol levels by decreasing the amount of harmful low-density lipoprotein (LDL) and increasing the quantity of beneficial high-density lipoprotein (HDL). It is typically prescribed to individuals with high cholesterol who are at risk of heart disease or stroke. This synthetic lipid-lowering agent has a high potency and selectivity towards the inhibition of HMG-CoA reductase, the primary enzyme responsible for cholesterol synthesis.

Upstream product

• 154057-56-4 3-(bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)-quinoline 
• 146578-99-6 <2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl>methyl(diphenyl)phosphine oxide 
• 154057-57-5 diethyl <2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl>methylphosphonate 
• 147526-32-7 pitavastatin calcium salt 
• 1391833-19-4 {[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}(triphenyl)phosphonium trifluoroacetate 
• 1391833-18-3 tricyclohexyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium trifluoroacetate 
• 1391833-16-1 tricyclohexyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium bromide 
• 1391833-14-9 tributyl{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl}phosphonium trifluoroacetate 
• 1391833-12-7 (4R,6S)-4-{[tert-butyl(dimethyl)silyl]oxy}-6-{(E)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]vinyl}tetrahydro-2H-pyran-2-one 
• 1391833-13-8 [2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl trifluoroacetate 
• 1068433-24-8 (4R,6S)-4-(tert-butyldimethylsilyloxy)-6-(dihydroxymethyl)tetrahydro-2H-pyran-2-one 
• 586966-54-3 (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid tert-butyl ester 
• 154057-58-6 <2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl>methyltriphenylphosphonium bromide 
• 147489-06-3 (4R,6S)-(E)-{6-[2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid tert-butyl ester 

Downstream Products

• 147526-32-7 pitavastatin calcium salt 

Relevant articles and documents

Furoxan azoxyNO donor type tadine derivative and preparation method thereof (by machine translation)

The invention discloses a furoxan azoxyNO donor type tadine derivative and a preparation method, and belongs to the technical field of chemical synthesis of medicines: the invention has the following structural formula shown in the general formula. Wherein. In addition, coumaric acid is selected as a connecting base, so that the curative effect; in addition, the compound disclosed by the invention can effectively release NO, and beneficial attempts are made for development of NO donor anti-atherosclerotic drugs in an external mode, and the method has the advantages of effectively improving the curative effect of drugs. 4 - R1 R2 (by machine translation)

3,5-dihydroxyhept-6-enoic acid derivative preparation method

The invention relates to a preparation method of 3, 5-dihydroxy-6-heptenoic acid derivatives. The preparation method comprises the steps of hydrolyzing crude statin ester to form a water-soluble alkali metal salt, extracting by using a solvent to remove impurities which cannot be dissolved into water, and converting at high yield to form ester with relatively high purity; then, purifying the ester by using a recrystallization way to obtain pure statin ester; and finally, converting the pure statin ester at high yield to form statin calcium, namely the 3, 5-dihydroxy-6-heptenoic acid derivatives. The 3, 5-dihydroxy-6-heptenoic acid derivatives, namely rosuvastatin calcium and pitavastatin calcium, synthesized by using the preparation method are high in purity and total yield, relatively low in cost and beneficial to mass production.

Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.